mary

This is an excerpt of an article in Duke-NUS Medicus 2021 issue 4. The (Wnt)ing way: Fighting cancer with ETC-159Wnts, which instruct cells on what they should become, are only found in multicellular animals, but not in single cell organisms such as yeast or amoebas, which don’t have as much need for proteins that communicate […]

While COVID-19, a disease caused by a virus, has captured the world’s attention over the past year, bacterial infections continue unabated. Furthermore, the emergence of more and more “superbugs” that are resistant to current treatment only serves to compound the issue, often leading to deadly outcomes. The Mycobacterium tuberculosis (Mtb) bacteria that causes tuberculosis (TB)

These compounds target the SARS-CoV-2 main protease and are active against other coronaviruses Lead series of proprietary 3CLpro inhibitors is available for out-licensing or co-development to expedite development and make an oral drug available to patients. As Singapore transitions “from pandemic to endemic”, its scientists are still working hard to find solutions to tackle COVID-19.

The Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development hosted at the Agency for Science, Technology and Research (A*STAR), and Hummingbird Bioscience, a clinical-stage biotech company, have entered a three-year partnership to develop novel antibodies for cancer immunotherapy. Immunotherapy can harness and enhance our body’s own immune defenses to fight

On 5 February 2021, Experimental Drug Development Centre (EDDC) hosted a visit by Second Minister for Trade and Industry, Dr Tan See Leng. This visit was part of Dr Tan’s monthly engagement visit with A*STAR research organisations to better understand the R&D scene in Singapore and to stay apprised of significant developments in A*STAR. Dr